An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Cardiovascular Systems, Inc. (CSII) is set to announce its operating results for the quarter ending December 31, 2022 before market opens on February 9, 2023. A conference call to discuss these results will occur at 9:00 a.m. ET the same day.
CSII specializes in developing medical devices for vascular and coronary disease, particularly with its orbital atherectomy system that treats plaque in arteries. This system aims to overcome limitations of existing treatments.
Positive
Focused on innovative solutions for treating vascular diseases.
Orbital atherectomy system addresses treatment limitations.
Negative
None.
ST. PAUL, Minn.--(BUSINESS WIRE)--
Cardiovascular Systems, Inc. (NASDAQ: CSII) plans to announce its operating results for the quarter ended December 31, 2022 before the market opens on Thursday, February 9, 2023, and will host a conference call at 9:00 a.m. ET that day to discuss those results.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company’s orbital atherectomy system treats calcified and fibrotic plaque in arterial vessels throughout the leg and heart and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. For more information, visit www.csi360.com and follow us on LinkedIn and Twitter.